Keyword: Bob Langer

Bind Therapeutics

Bind rose to prominence on the strength of its pedigree and venture backing as much as its technology. But its nanotechnology platform came up short, leaving the company to seek a Big Pharma partner to stay afloat. No one came to the rescue, and Bind sold off its assets to Pfizer for $40 million.